Featured Courses

COVID-19 Infections and Hematologic Disturbances

AMA PRA Category 1 Credit(s)^TM

This education will provide physicians with the resources necessary to discuss treatment options with patients, payers and administrators to ensure that each stakeholder understands the importance of those options for the management of patients with hematologic malignancies and COVID-19.

Updates in AML for Community Clinicians | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

Have you heard about the latest clinical advances in AML therapy? Join Drs Strickland and Wang as they discuss recent science that provides guidance for the care team on the use of newly approved and novel strategies for AML management.

Debating Myeloma Care Strategies: Time to Choose Sides! | myCME

AMA PRA Category 1 Credit(s)^TM

This activity follows a debate format and features audience polling relating to the proffered arguments, as well as panel discussions.

EXPLORING ALL POSSIBILITIES: Improving Outcomes for Adolescents and Young Adults With Acute Lymphoblastic Leukemia | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AANP Contact Hour(s)

This 60-minute online activity features a tumor board-like discussion by an interprofessional faculty team who present two patient cases and explore treatment regimens for adolescents and young adults with acute lymphoblastic leukemia (ALL).

Hematology Consults: Current Landscape of GVHD – Module 1 | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

Allogeneic hematopoietic stem-cell transplantation (alloHSCT) is favored for treating patients with acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndromes. AlloHSCTs rely on the immunoreactivity of the donor graft for a potent antitumor response, however, alloHSCTs are associated with acute and chronic graft versus host disease (GVHD), which can affect many different organs and tissues.

Hematology Consults: Acute & Chronic GVHD – Module 2 | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

There is little guidance about choosing the most appropriate therapy for patients with graft vs host disease (GVHD) after undergoing an allogeneic hematopoietic stem cell transplantation (alloHSCT). Until the recently, steroids were the only agents with proven ability to treat patients with GVHD.

Breakthroughs for Obese Patients with VTE | myCME

AMA PRA Category 1 Credit(s)^TM

What is the latest evidence for VTE prophylaxis and treatment in obese patients and how is this different from the current guidelines? In this activity, expert cardiology faculty cover the most recent data and guideline limitations on VTE prevention and management. Roundtable discussion is included to provide practical insight to help clinicians apply knowledge to their practice and help them optimize anticoagulant therapy and develop treatment plans in their obese patients.

Advancing the Care of Patients with Sickle Cell Disease | myCME

AMA PRA Category 1 Credit(s)^TM

Dr. Biree Andemariam and Dr. Laura De Castro explore current recommendations for sickle cell disease management, review available agents, and discuss strategies to encourage clinical trial participation among patients. By participating, you will learn the latest information on this challenging disease.

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

In this CME Outfitters Live and OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.

Meeting the Challenges in Management of Sickle Cell Disease | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

Join Michael DeBaun, MD, MPH, and Collin Montgomery, APRN, as they discuss the acute and chronic complications experienced by individuals with sickle cell disease and the barriers they often encounter.

The Role of Maintenance Therapy in AML | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

As the research of maintenance strategies in acute myeloid leukemia (AML) advances, it is important for clinicians stay abreast of study designs and results from clinical trials. This activity will discuss a patient case study and explain treatment decisions and rationale for maintenance strategies in AML.

Disparities and Improving the Care of Advanced HCC in the Hispanic Community | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

Significant race and ethnicity-specific disparities in HCC care account in many respects for the increased incidence—approximately 36%—of HCC among Hispanics, who are more likely to present late and less likely to receive any HCC-directed treatment. However, improved screening and surveillance guidelines and greater understanding of the pathophysiology and molecular pathways in HCC has led to the emergence of targeted treatment.